Skip to main content

Table 4 The multivariate cox regression analysis in cervical cancer patients

From: Connecting METTL3 and intratumoural CD33+ MDSCs in predicting clinical outcome in cervical cancer

Factors Disease-free survival Overall survival
HR (95%CI) P value HR (95%CI) P value
The levels of METTL3, CD33 in tumor and tumor-infiltrating immune cells (n = 197)
 Clinical stage (I/II–IV) 3.827 (1.585–9.241) 0.003 4.248 (1.886–9.571)  < 0.001
 Tumor (T) status (1/2–4)
 Nodal (N) status (0/1) 3.219 (1.197–8.653) 0.021
 METTL3 in tumor cells (low/high) 3.157 (1.181–8.438) 0.022 3.271 (1.303–8.213) 0.012
 METTL3 in tumor-infiltrating immune cells (low/high) 3.368 (1.080–10.502) 0.036 1.006(0.202–5.013) 0.994
 Number of CD33+ MDSCs (low/high) 3.958(1.138–13.767) 0.031
The levels of METTL3, CD33 in tumor and tumor-infiltrating immune cells in stage II–IV (n = 70)
 Tumor (T) status (1/2–4) 0.173 (0.023–1.317) 0.090
 METTL3 in tumor cells (low/high) 6.725 (1.576–28.696) 0.010 5.140 (1.286–20.548) 0.021
 METTL3 in tumor-infiltrating immune cells (low/high) 2.053 (0.483–8.726) 0.330 2.149 (0.541–8.540) 0.277
 Number of CD33+ MDSCs (low/high) 8.802 (1.136–68.233) 0.037
  1. The significant different factors in univariate analysis were analyzed by multivariate analysis, and the factors which were not significant in univariate analysis were not included